Skip to main content
. Author manuscript; available in PMC: 2012 Aug 16.
Published in final edited form as: Eur J Pharmacol. 2011 May 7;664(1-3):45–53. doi: 10.1016/j.ejphar.2011.04.059

Fig. 3. Myocardial microvascular response to adenosine diphosphate (ADP).

Fig. 3

The microvascular relaxation response to the endothelial-dependent vasorelaxing agent ADP is dysfunctional in the HCD group and normalized to the control in the HCD-R group (*P<0.001). Addition of L-NG-Nitroarginine methyl ester, a specific nitric oxide inhibitor, with ADP to control vessels demonstrates a significant decrease in microvascular vasorelaxation as compared to ADP alone (*P<0.001).